The fighter, the saint, and the odd man out: the executives who will defend pharma before Congress

One’s a college dropout. One’s a self-proclaimed street fighter. And one survived a presidential tweetstorm.

Meet pharma’s new Gang of Seven, a disparate group of executives about to face congressional questions on what they have in common: Their companies sell drugs, and drugs keep getting more expensive.